- Home
- IBIO vs PHGE Comparison
IBIO vs PHGE Comparison
Compare IBIO & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- PHGE
- Stock Information
- Founded
- IBIO 2008
- PHGE 2015
- Country
- IBIO United States
- PHGE Israel
- Employees
- IBIO N/A
- PHGE N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- IBIO Health Care
- PHGE Health Care
- Exchange
- IBIO Nasdaq
- PHGE Nasdaq
- Market Cap
- IBIO 11.9M
- PHGE 10.4M
- IPO Year
- IBIO N/A
- PHGE N/A
- Fundamental
- Price
- IBIO $0.93
- PHGE $0.47
- Analyst Decision
- IBIO Strong Buy
- PHGE Strong Buy
- Analyst Count
- IBIO 2
- PHGE 1
- Target Price
- IBIO $5.50
- PHGE $15.00
- AVG Volume (30 Days)
- IBIO 2.1M
- PHGE 441.1K
- Earning Date
- IBIO 11-11-2025
- PHGE 08-13-2025
- Dividend Yield
- IBIO N/A
- PHGE N/A
- EPS Growth
- IBIO N/A
- PHGE N/A
- EPS
- IBIO N/A
- PHGE N/A
- Revenue
- IBIO $400,000.00
- PHGE N/A
- Revenue This Year
- IBIO N/A
- PHGE N/A
- Revenue Next Year
- IBIO N/A
- PHGE N/A
- P/E Ratio
- IBIO N/A
- PHGE N/A
- Revenue Growth
- IBIO 77.78
- PHGE N/A
- 52 Week Low
- IBIO $0.56
- PHGE $0.34
- 52 Week High
- IBIO $6.89
- PHGE $1.16
- Technical
- Relative Strength Index (RSI)
- IBIO 64.71
- PHGE 44.76
- Support Level
- IBIO $0.77
- PHGE $0.45
- Resistance Level
- IBIO $0.97
- PHGE $0.51
- Average True Range (ATR)
- IBIO 0.07
- PHGE 0.03
- MACD
- IBIO 0.01
- PHGE -0.01
- Stochastic Oscillator
- IBIO 82.62
- PHGE 19.83
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).